Trials / Completed
CompletedNCT01700179
Evaluation of Safety, Tolerability, and Antiviral Activity of ACH-0143102 Plus Ribavirin In Treatment-naive Hepatitis C Virus Infection Genotype 1b Participants
A Phase 1b, Open-label, Pilot Study to Evaluate the Safety, Tolerability, and Antiviral Activity of Oral ACH-0143102 Administered in Combination With Ribavirin for 12 Weeks in Treatment-naive Subjects With Chronic Hepatitis C Virus Infection Genotype 1b
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 8 (actual)
- Sponsor
- Alexion Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study was to evaluate the safety, tolerability, and efficacy of 12 weeks of treatment with ACH-0143102 and ribavirin in genotype 1b (GT1b), treatment-naive, hepatitis C virus (HCV) participants.
Detailed description
A Phase 1b, pilot study that evaluated the safety, tolerability, and antiviral activity of oral ACH-0143102 administered in combination with ribavirin for 12 weeks in treatment-naive participants with chronic HCV GT1b.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ACH-0143102 | |
| DRUG | Ribavirin |
Timeline
- Start date
- 2012-09-01
- Primary completion
- 2013-09-01
- Completion
- 2013-09-01
- First posted
- 2012-10-04
- Last updated
- 2023-08-29
- Results posted
- 2014-10-03
Source: ClinicalTrials.gov record NCT01700179. Inclusion in this directory is not an endorsement.